Clinical trials: Eczema, Atopic
Atopic Dermatitis
The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis
This clinical trial will study the effects of PUFA supplementation during pregnancy and lactation period on fatty acid composition in human milk and plasma of the mothers and the clinical outcome of atopic dermatitis in infants…
- Trial name
- NCT01936194
- Testing
- DHA+EPA, High Olive Oil, DHA
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
Atopic Dermatitis, Eczema Herpeticum
Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis
Atopic Dermatitis (AD), also known as eczema, is a skin disease that causes the skin to be hot, dry and scaly, and have severe itching. There are different kinds of eczema.
- Trial name
- NCT00438022
- Where
- Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteer, Atopic Dermatitis
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
This study will test an experimental study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B).
- Trial name
- AURA-AD (NCT07527923)
- Testing
- REGN20423
- Where
- 9 sites in United States, Belgium
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application
The main goal of this present study is evaluate the decreasing of necessity of topic corticoids usage to control outbreaks of light to moderate atopic dermatitis by using the correct emollients.
- Trial name
- NCT01063218
- Testing
- Emollient - Cetaphil Advanced
- Where
- 2 sites in Brazil
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Galderma Brasil Ltda.
Atopic Dermatitis, Eczema
Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms
This interventional, double-blind, randomized, placebo-controlled study aims to evaluate the effect of a marine by-product hydrolysate supplementation on the reduction of atopic dermatitis symptoms.
- Trial name
- NCT06268847
- Testing
- ACT01, ACT02
- Where
- Spain
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Atopic Dermatitis (AD)
Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.
A 56-day clinical study evaluated Revodiol Calming Cream on pediatric and adult participants with mild to moderate atopic-prone skin under dermatological supervision.
- Trial name
- NCT07301658
- Testing
- Novel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract.
- Where
- Spain
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- i+Med S.Coop.
Atopic Dermatitis, Contact Dermatitis
Exploratory Study of Natural Killer Cells in Human Skin
Natural Killer (NK) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.In a first time…
- Conditions
- Atopic Dermatitis, Contact Dermatitis, Psoriasis, Lichen Planus
- Trial name
- NCT00824889
- Testing
- Biopsy and sample of blood
- Where
- France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Atopic Dermatitis
A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis
A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 gel after transdermal administration in…
- Trial name
- Shaperon (NCT03492398)
- Testing
- HY209
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Shaperon
Psoriasis, Atopic Dermatitis
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
The object of this research study is to examine these associations in children as very little is known about psoriasis and cardiovascular risk factors in the pediatric population.
- Trial name
- NCT00879944
- Testing
- Blood pressure, Height, Weight
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Atopic Dermatitis (AD), Eczema
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)…
- Trial name
- NCT07453602
- Testing
- ARQ-234
- Where
- 7 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis, Infant, Newborn
Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood
In this study, it will be investigated if symptoms of atopic dermatitis of children with high familial risk will be delayed beyond the 6th or even 12th month of life by applying the SanaCutan Basiscreme.
- Trial name
- MOPAD (NCT04398758)
- Testing
- SanaCutan Basiscreme
- Where
- 10 sites in Germany
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Infectopharm Arzneimittel GmbH
Dermatitis, Atopic
The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis
Atopic dermatitis is the most common chronic inflammatory skin disease in children and severely affects quality of life (QoL) of patients and their parents.
- Trial name
- NCT02343861
- Testing
- Tailored leaflet group, Control group
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Atopic Dermatitis (AD)
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
This is a Phase I/II Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT07182864
- Testing
- MH004 0.1% Ointment, MH004 0.3% Ointment, MH004 1.0% Ointment
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Atopic Dermatitis
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
The purpose of this study is to see how a medicine called PF-08049820 affects how other medicines move through the body. This information will help plan future studies.
- Trial name
- NCT07190430
- Testing
- PF-08049820, Midazolam, Dabigatran Etexilate
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Adults
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves.
- Trial name
- NCT07284173
- Testing
- PF-08049820, Rabeprazole
- Where
- 2 sites in China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dermatitis, Atopic
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636.
- Trial name
- NCT07604324
- Testing
- DCY636
- Where
- Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Nature, Human
Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis
The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity.
- Conditions
- Atopic Dermatitis, Nature, Human, Microbial Colonization, Immune System and Related Disorders
- Trial name
- BIWE (NCT06390696)
- Testing
- Microbial intervention
- Where
- 2 sites in Finland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Natural Resources Institute Finland
Atopic Dermatitis, Ichthyosis Vulgaris
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
The investigators' primary objective is to identify common and rare mutations in the filaggrin gene in African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris.
- Trial name
- NCT01016106
- Testing
- Buccal Swab
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Healthy Adults, Atopic Dermatitis
Sweat and Gas Sensor for Healthy Skin and Atopic Dermatitis
Pilot study of a wearable gas and sweat skin sensor
- Conditions
- Healthy Adults, Atopic Dermatitis, Wearables, Sweat Sensor
- Trial name
- NCT03874039
- Testing
- Gas sensor, Sweat Sensor
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Dermatitis Atopic
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic…
- Trial name
- PELISTAD (NCT04718870)
- Testing
- Dupilumab SAR231893
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sanofi